Coherus BioSciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring between May 21, 2018, and May 25, 2018. The filing details the completion of an underwritten public offering of common stock and the results of the Company's 2018 Annual Meeting of Stockholders held on May 23, 2018.
Key Financial Metrics
- Capital Raised: The Company completed the sale of 5,948,274 shares of Common Stock.
- Net Proceeds: Approximately $80.8 million, after deducting underwriters' discounts, commissions, and estimated offering expenses.
- Offering Price: Shares were sold at a public offering price of $14.50 per share.
- Underwriter Purchase Price: $13.63 per share.
- Option Exercise: Underwriters exercised their option in full to purchase an additional 775,861 shares.
- Outstanding Shares: As of the April 2, 2018 record date, there were 60,154,225 shares outstanding.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the significant increase in cash liquidity resulting from the equity offering. The Company raised approximately $80.8 million in net proceeds, substantially increasing its cash position compared to the period prior to the offering. Additionally, the share count increased by approximately 5.95 million shares upon the completion of the offering.
Outlook, Management Commentary, and Risks
- Lock-Up Period: The Company, its directors, executive officers, and certain affiliated stockholders agreed not to sell or transfer any Common Stock for 60 days following May 22, 2018, without written consent from the underwriters.
- Corporate Governance: Stockholders elected Class I director nominees Christos Richards and V. Bryan Lawlis, Ph.D., to serve until the 2021 Annual Meeting. Stockholders also ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Risks: The filing notes customary representations, warranties, and indemnification obligations within the Underwriting Agreement but does not detail specific operational or market risks beyond standard securities law liabilities.
Key Facts for Investor Verification
- Verify the exact use of the $80.8 million in net proceeds as disclosed in the prospectus supplement.
- Confirm the updated total share count and diluted earnings per share impact following the issuance of 5,948,274 new shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Monitor the expiration of the 60-day lock-up period for insiders and affiliated stockholders.